STRASBOURG, France--(BUSINESS WIRE)--
Regulatory News:
Transgene (Paris:TNG) today announced its financial reporting dates for 2018:
|
March 21: |
2017 Fiscal Year Results | ||||
|
April 26: |
First Quarter 2018 Financial Results | ||||
|
May 23: |
Annual Shareholders' Meeting | ||||
|
September 19: |
First Half 2018 Financial Results | ||||
|
October 25: |
Third Quarter 2018 Financial Results |
About Transgene
Transgene (Euronext: TNG), part of
Institut Mérieux, is a publicly traded French biotechnology company
focused on designing and developing targeted immunotherapies for the
treatment of cancer and infectious diseases. Transgene’s programs
utilize viral vector technology with the goal of indirectly or directly
killing infected or cancerous cells. The Company’s lead clinical-stage
programs are: TG4010, a therapeutic vaccine against non-small cell lung
cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a
therapeutic vaccine against HPV-positive head and neck cancers. The
Company has several other programs in clinical and preclinical
development, including TG1050 (chronic hepatitis B) and TG6002 (solid
tumors). Transgene is based in Strasbourg, France, and has additional
operations in Lyon, as well as a joint venture in China.
Additional
information about Transgene is available at www.transgene.fr.
Follow
us on Twitter: @TransgeneSA
View source version on businesswire.com: http://www.businesswire.com/news/home/20171221005609/en/
